HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Emanuela Troiani Selected Research

Vincristine (Oncovin)

8/2005A new schedule of CHOP/rituximab plus granulocyte-macrophage colony-stimulating factor is an effective rescue for patients with aggressive lymphoma failing autologous stem cell transplantation.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown:


Emanuela Troiani Research Topics

Disease

1Multiple Myeloma
01/2021
1Acute Myeloid Leukemia (Acute Myelogenous Leukemia)
09/2014
1Neutropenia
07/2007
1Leukopenia
08/2005
1Leukemia
08/2005
1Lymphoma (Lymphomas)
08/2005
1Non-Hodgkin Lymphoma (Lymphosarcoma)
08/2005

Drug/Important Bio-Agent (IBA)

1LactaseIBA
01/2021
1Oxidoreductases (Dehydrogenase)IBA
01/2021
1Gemtuzumab (Mylotarg)FDA Link
09/2014
1Cytarabine (Cytosar-U)FDA LinkGeneric
09/2014
1Anti-Bacterial Agents (Antibiotics)IBA
07/2007
1Rituximab (Mabthera)FDA Link
08/2005
1Prednisone (Sone)FDA LinkGeneric
08/2005
1Vincristine (Oncovin)FDA LinkGeneric
08/2005
1Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF)IBA
08/2005
1CytokinesIBA
08/2005
1Cyclophosphamide (Cytoxan)FDA LinkGeneric
08/2005

Therapy/Procedure

2Therapeutics
09/2014 - 07/2007
2Stem Cell Transplantation
09/2014 - 08/2005
1Transplantation
08/2005
1Homologous Transplantation
08/2005